I'm still a believer in ARQL risk-reward here and continue to hold (even if it is one of my smallest positions). It is nice to see shares finally rebound a bit. Tivantinib is obviously the big shot on goal being in P3 but still plenty of other shots on goal (Akt in orphan maybe most interesting?) and still plenty of cash. I will listen to recent CC and post any meaningful notes.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.